Cytiva Launches ÄKTA readyflux TFF System 500 to Advance Low-Volume Therapeutic Manufacturing

24 July 2025 | Thursday | News

Responding to industry demand, Cytiva unveils its latest scalable and user-friendly TFF solution to enhance efficiency, consistency, and technology transfer for small-batch applications in advanced biologics and mRNA therapies.

Cytiva, a Danaher company and a leader in the life sciences industry, is expanding its ÄKTA portfolio with the addition of a system designed to optimize smaller-scale manufacturing. The ÄKTA readyflux TFF system 500 was developed in direct response to customer feedback indicating a rising need for efficient handling of low-volume applications in advanced therapeutic development, including viral vectors, monoclonal antibodies (mAbs), antibody drug conjugates (ADCs), and mRNA-based therapeutics. 
Ludovic Brellier, President, Hardware Solutions, Cytiva, says: “Customers need robust solutions with industry leading technology, but also operational flexibility to manage lower volumes. The ÄKTA readyflux TFF system 500 is designed to provide these capabilities while maintaining the easy-to-use functions of the platform.” 
ÄKTA readyflux TFF system 500 addresses industry challenges 
The ÄKTA readyflux TFF system 500 is designed to support drug developers in bringing their therapeutics to market faster, more efficiently, and with greater reliability. The industry issues addressed include: 
  • Scalability: For drug developers who struggle with scaling their processes from small-scale development to clinical and commercial manufacturing, the ÄKTA readyflux TFF system 500 offers scalability, while reducing risks and ensuring a smooth transition across different stages of development. 
  • Efficiency in low-volume applications: The system is designed to handle applications such as viral vectors, monoclonal antibodies (mAbs), antibody drug conjugates (ADCs), and mRNA-based treatments efficiently, enabling maximum recovery with minimal loss. 
  • Technology transfers: Moving processes from one stage of development to another can be complex and time-consuming. The system simplifies technology transfers, making the process more consistent, thus accelerating development timelines. 
  • Time and resource management: Traditional systems may require extensive programming expertise and lengthy batch changeover times, leading to inefficiencies and increased downtime. The ÄKTA readyflux TFF system 500 features a single-use flow kit and easy-to-use UNICORN software, minimizing the need for specialized skills and reducing downtime. 
  • Batch-to-batch consistency: Ensuring homogeneous mixing and batch-to-batch consistency is critical to maintaining product quality, maximizing yield, and enhancing process efficiency for low-volume applications. The ÄKTA readyflux TFF system 500 features active mixing via magnetic stirring, delivering controlled, reproducible mixing that ensures consistent performance across every batch. 
     
The ÄKTA readyflux TFF system 500 will be available to order August 11 and deliveries are expected in late 2025. 

 

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close